Stocktoria
Monte Rosa Therapeutics, Inc. GLUE
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-24
Monte Rosa Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -43.8% | -107.3% | — | — | — |
| Net margin | -31.2% | -96.1% | — | — | — |
| FCF margin | -22.2% | 50.3% | — | — | — |
| Return on assets | -8.6% | -16.6% | -44.6% | -31.7% | -20.2% |
| Return on equity | -16.6% | -32.6% | -75.5% | -40.0% | -21.3% |
| Current ratio | 6.12 | 2.40 | 5.07 | 10.79 | 20.96 |
| Revenue growth | 63.5% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001826457 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.